Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Phase 2

Completed

Conditions: Multiple Endocrine Neoplasia Type 2A
Stage IV Thyroid Gland Medullary Carcinoma AJCC v7
Sporadic Thyroid Gland Medullary Carcinoma
Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
Locally Advanced Thyroid Gland Medullary Carcinoma
Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
Hereditary Thyroid Gland Medullary Carcinoma
Stage III Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Multiple Endocrine Neoplasia Type 2B

Interventions: Drug: Sorafenib Tosylate

Registration Number: NCT00390325

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally advanced), or has returned after a period of improvement (recurrent). Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Detailed Description: PRIMARY OBJECTIVES:

I. To assess objective response rate of sorafenib tosylate (sorafenib \[BAY 43-9006\]) in metastatic medullary thyroid carcinoma in setting of inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial medullary thyroid carcinoma (FMTC).

II. To assess objective response rate of sorafenib (BAY 43-9006) in sporadic metastatic medullary thyroid carcinoma.

SECONDARY OBJECTIVES:

I. To assess toxicity of sorafenib (BAY 43-9006) in patients with metastatic medullary thyroid carcinoma.

II. Measure serum tumor markers calcitonin and carcinoembryonic antigen (CEA) pre-, during, and post-treatment to correlate with disease response.

III. Correlate nuclear medicine functional imaging (fludeoxyglucose F 18 \[F-18 fluorodeoxyglucose\] positron emission tomography \[PET\] scan) data obtained at pre-, during, and post-treatment with tumor response.

IV. Correlate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data obtained at pre-, during, and post-treatment with changes in tumor permeability and vascularity with tumor response.

V. Perform pharmacogenomic studies on procured peripheral blood mononuclear cells (PBMCs) if clinical responses are observed.

VI. To correlate between the degree of retrovirus-associated sequence (Ras)-mitogen-activated protein kinase (MAPK) signaling inhibition and vascular endothelial growth factor (VEGF) expression in the tumor and clinical response.

VII. To correlate between the presence and type of ret proto-oncogene (RET) gene defects in tumor and clinical response.

OUTLINE:

Patients receive sorafenib tosylate orally (PO) twice daily (BID) in the absence of disease progression or unacceptable toxicity.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 21

Inclusion Criteria

ELIGIBILITY CRITERIA SPECIFIC FOR ARM A
Histologically confirmed medullary thyroid carcinoma under the clinical setting of inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial medullary thyroid carcinoma (FMTC)
ELIGIBILITY CRITERIA SPECIFIC FOR ARM B
Histologically confirmed medullary thyroid carcinoma under the clinical setting of sporadic medullary thyroid carcinoma (MTC)
ELIGIBILITY CRITERIA COMMON FOR ARMS A AND B
Patients must have measurable disease
Metastatic and/or locally advanced or locally recurrent disease
Oral or intravenous (IV) bisphosphonates therapy will be allowed for patients with bony metastasis at the investigator's discretion; bisphosphonate usage should be recorded if used since these agents may have anti-farnesyl transferase activity and may have some therapeutic effect in combination with sorafenib
Life expectancy must be >= six months
Patients must have an Eastern Cooperative Oncology Group performance status 0-2
Leukocytes >= 2,000/uL (10 days prior to patient enrollment)
Absolute neutrophil count >= 1,000/uL (10 days prior to patient enrollment)
Platelets >= 100,000/uL (10 days prior to patient enrollment)
Total bilirubin =< within 2 x upper limit of normal (10 days prior to patient enrollment)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< within 3 x upper limit of normal (10 days prior to patient enrollment)
Serum creatinine within normal institutional limits OR creatinine clearance > 30 mL/min (by Cockcroft-Gault formula) (10 days prior to patient enrollment)
The effects of sorafenib (BAY 43-9006) on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because kinase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 30 days after completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

EXCLUSION CRITERIA FOR ARM A AND B
Patients who have had systemic anti-tumor therapy (such as chemotherapy, biologic modifiers or antiangiogenic therapy) within 4 weeks (6 weeks if nitrosourea or mitomycin chemotherapy) prior to study entry
Patients who have had external beam radiation therapy within 1 week or if the adverse events associated with radiation are not resolved to grade 1 or less prior to study entry
Prior therapy with sorafenib (BAY 43-9006), ZD 6474 or AMG-706
Patients currently receiving any other tumor-specific therapy for thyroid cancer or investigational therapy; patients receiving adjuvant hormonal therapy for a second primary (such as breast cancer or prostate cancer) are allowed to participate as far as there are no known drug interactions
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib (BAY 43-9006)
Patients unable to swallow sorafenib tablets (e.g. any condition that impairs patient's ability to swallow pills)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, or psychiatric illness/social situations that would limit compliance with study requirements
Patients with any evidence of a bleeding diathesis
Patients actively receiving anticoagulation with therapeutic intent; prophylactic anticoagulation (i.e. low dose warfarin) or venous or arterial access devices is allowed provided that the prothrombin time (PT), international normalized ratio (INR) or partial thromboplastin time (PTT) are normal
Pregnant women or women who are breast-feeding are excluded from this study because sorafenib (BAY 43-9006) is an investigational agent and teratogenicity has not been evaluated yet; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sorafenib (BAY 43-9006), breastfeeding should be discontinued if the mother is treated with sorafenib (BAY 43-9006)
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with sorafenib (BAY 43-9006); patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy
Patients taking the cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin or St. John's wort due to potential drug interactions with sorafenib

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (sorafenib tosylate)	Sorafenib Tosylate	Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer	Up to 4 weeks after last dose of sorafenib tosylate	Measured using MRI scans. Determined using Response Evaluation Criteria in Solid Tumors/World Health Organization response criteria. 95% confidence interval will be calculated to estimate the frequency of response.

Secondary Outcome Measures

Name	Time	Method
Selected Polymorphisms of Genes Influencing Sorafenib Tosylate Metabolism and/or Resistance Genes That May Predict Response or Toxicity	Baseline	Changes will be correlated with toxicity and clinical response to therapy.
Number of Patients With Decreased Calcitonin Levels	Up to 4 weeks after last dose of sorafenib tosylate	Identifying the number of patients with decreased calcitonin levels
Patient With Decreased Carcinoembryonic Antigen (CEA) Levels	Up to 4 weeks after last dose of sorafenib tosylate	Identify the number of patients with decreased Carcinoembryonic Antigen (CEA) levels
Percent of Baseline Dynamic-Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Exchange Rate Constant (Kep)	Up to 4 weeks after last dose of sorafenib tosylate	Median decrease in exchange rate Kep in index lesions
Degree of Ras-MAPK Signaling Inhibition in the Tumor	Up to 4 weeks after last dose of sorafenib tosylate	Identify the number of patients with degree of Ras-MAPK signaling inhibition
Degree of Vascular Endothelial Growth Factor (VEGF) Expression in the Tumor	Up to 4 weeks after last dose of sorafenib tosylate	Correlated with clinical response.
Standardized Uptake Value (SUV Max) as Measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET)	Up to 4 weeks after last dose of sorafenib tosylate	Identify the median SUV at baseline and 8 week follow up as measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET).
Number of Patients With Toxicity, Graded Using the Revised National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0	Up to 4 weeks after last dose of sorafenib tosylate	Toxicities were graded for patients using the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
Number of Participants With Ret Proto-Oncogene (RET) Gene Defects in the Tumor	Baseline	Percent of patients with RET mutations

Trial Locations

Locations (3): Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Ohio State University Comprehensive Cancer Center
🇺🇸
Columbus, Ohio, United States
Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States